drugset / Trial / NCT02595879

Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer

NCT02595879

Phase 1 Active not recruiting 21 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase I trial studies the side effects and best dose of triapine when given with radiation therapy and cisplatin in treating patients with stage IB2-IVA cervical or vaginal cancer. Triapine may stop the growth of cancer cells by blocking an enzyme needed for cell growth. Cisplatin is a drug used in chemotherapy that kills cancer cells by damaging their deoxyribonucleic acid (DNA) and stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Adding triapine to standard treatment with cisplatin and radiation therapy may kill more cancer cells.

Timeline

Start
2019-09-18
Primary completion
2023-06-04
Completion
2027-04-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Triapine Small molecule 100 mg Intravenous
Background Cisplatin Other / unclassified Intravenous